Elan accuses rebel director of insider trading

In an unusual twist to a boardroom spat at Elan, the Irish drugmaker has reported one of its own directors to the U.S. Securities and Exchange Commission for potential insider-trading allegations. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.